Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
Alexander PanRachel E ReingoldJimmy L ZhaoAndrea MoyLukas KraehenbuehlGeorge DranitsarisSean M McBrideHoward I ScherMarisa A KollmeierHan XiaoDana E RathkopfMario E LacouturePublished in: The Journal of urology (2022)
Apalutamide-related dAEs are frequent and can be managed with topical ± oral steroids. With expanded approval of apalutamide, dAE identification and management are essential.